Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine
CONCLUSIONS: Results suggest that a Fall 2023 COVID-19 vaccine would reduce total numbers of COVID-19-related infections, hospitalizations, and deaths.PMID:38429154 | DOI:10.1016/j.vaccine.2024.01.093 (Source: Vaccine)
Source: Vaccine - March 1, 2024 Category: Allergy & Immunology Authors: Michele Kohli Michael Maschio Amy Lee Ataru Igarashi Source Type: research
Prevalence, serogroup distribution and risk factors of Neisseria meningitidis carriage in high school and university students in Hungary
In conclusion, we have found high asymptomatic meningococcus carriage rate among high school students and young adults, however, the majority of the colonizing meningococci were non-typable.PMID:38423809 | DOI:10.1016/j.vaccine.2024.02.064 (Source: Vaccine)
Source: Vaccine - February 29, 2024 Category: Allergy & Immunology Authors: Annam ária Huber Eszter Kov ács Andrea Horv áth Judit Sahin-T óth Ákos Kaptás Emese Juh ász Katalin Krist óf Orsolya Dobay Source Type: research
Retrospective cohort study exploring the impact of universal Tuberculosis (TB) vaccination cessation on the epidemiology of paediatric TB in Ireland, 2011-2021
CONCLUSIONS: Universal BCG cessation has not yet directly impacted on TB cases among 0-6 year olds in Ireland. However, interruption of the previously declining temporal trend in this cohort during universal vaccination may be an early warning of a future increase. Paediatric TB cases remain an important cohort for timely surveillance to monitor trends in this primarily unvaccinated cohort to evaluate the long-term effects.PMID:38423810 | DOI:10.1016/j.vaccine.2024.02.061 (Source: Vaccine)
Source: Vaccine - February 29, 2024 Category: Allergy & Immunology Authors: Sarah Jackson Zubair Kabir Catherine Comiskey Source Type: research
Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial
CONCLUSION: Our findings support the non-inferiority of the FluGuard vaccine to the Vaxigrip vaccine regarding immunogenicity and safety.CLINICAL TRIAL REGISTRY: The study protocol was approved by the Iranian Registry of Clinical Trials (IRCT20210901052358N5).PMID:38423811 | DOI:10.1016/j.vaccine.2024.02.073 (Source: Vaccine)
Source: Vaccine - February 29, 2024 Category: Allergy & Immunology Authors: Davood Yadegarynia Amirreza Keyvanfar Hossein Keyvani Shabnam Tehrani Shahnaz Sali Sara Abolghasemi Source Type: research
Parental willingness to accept and pay human papillomavirus vaccine for boys aged 9-14 in a metropolis area of China: Evidence for developing a vaccination strategy
CONCLUSION: Parents have high WTA and WTP HPV vaccine for boys aged 9-14 in Shanghai, which may provide evidence for preparing HPV vaccination strategy. Acceptance of HPV vaccines and roll-out in boys could be enhanced through the availability of government subsidy mechanism and domestic HPV vaccines.PMID:38423812 | DOI:10.1016/j.vaccine.2024.02.076 (Source: Vaccine)
Source: Vaccine - February 29, 2024 Category: Allergy & Immunology Authors: Weiyu Zhou Xiang Guo Jia Lu Xinyue Lu Xiaoya Fu Yihan Lu Source Type: research
